Сучасний погляд на роль фолатів у профілактиці перинатальних проблем

І. А. Жабченко

doi:10.18370/2309-4117.2019.46.57-61

Authors

І. А. Жабченко SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”, Ukraine https://orcid.org/0000-0001-5622-5813

DOI:

https://doi.org/10.18370/2309-4117.2019.46.57-61

Keywords:

fetal congenital anomalies, folic acid, metafolin, Femibion Natalcare

Abstract

One of the vital vitamins is folic acid (FA), or vitamin B9. The biggest positive effects of FA show precisely during pregnancy. It is necessary for normal growth, tissue development and proliferation, hematopoiesis and embryogenesis; for uterus, placenta growth and erythropoiesis. There is a correlation between folate deficiency in pregnant women and the risk of birth defects, not only related to the neural tube defect, but also other defects. So, today the first place among the folate-induced defects in the fetus development is heart failure, followed by a defect of the nervous tube, limb defects and non-enlargement of the palate and upper lip, urinary system defects.

Therefore, there is a question about the external FA provision in the form of drugs for pregnant. But all synthetic drugs with FA are chemical inactive compounds, which in the human body have to go through a cascade of transformations. FA is not digested due to the genes polymorphism of the folate cycle enzymes, which occurs in about half of women. Therefore an increase in the FA dose is not a solution to this problem, since the accumulation of non-metabolized biologically inactive FA form in blood will lead to blockade of active folate receptors and increase the folate deficiency. Therefore, a stable molecule of synthetic biologically active folate form based on the FA metabolite L-5-methyltetrahydrofolate (MTHF) was created, which differs by the presence of calcium ion. The substance is called “metafolin”. It quickly dissolves in the body into calcium ions and L-5-MTHF, which continues to perform all important functions of folate. It has been proven in clinical trials that, regardless of the genotype and activity of the methylenetetrahydrofolate reductase in women, metafolin have a higher bioavailability and more effectively promotes increased folate levels in plasma than the same dose of FA. On this basis a fundamentally new drug Femibion Natalcare for pregnancy and lactation was created.

Author Biography

І. А. Жабченко, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”

MD, professor, сhief of the Department of pathology of pregnancy and childbirth

References

Radzinskiy, V.E., Ryabinkina, T.S., Bril, Y.A., Simonovskaya, K.Y. Correction of the diet for pregnant women: evidence data (news letter). Editorial board of Status Praesens Journal (2018): 28 p.
Johnston, R.B. “Will increasing folic acid in fortified grain products further reduce neural tube defects without causing harm? Consideration of the evidence.” Pediatric Research 63.1 (2008): 2–8.
Honein, M.A., Paulozzi, L.J., Mathews, T.J., et al. “Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects.” JAMA 285 (2001): 2981–6.
De Wals, P., et al. “Reduction in neural-tube defects after folic acid fortification in Canada.” New Engl J Med 357.2 (2007): 135– 42.
Wills, L. “Treatment of “pernicious anaemia of pregnancy” and “tropical anaemia” with special reference to yeast extract as a curative agent (1931).” Natl Med J India 26.2 (2013): 117–22.
Hibbard, B.M. “The role of folic acid in pregnancy; with particular reference to anaemia, abruption and abortion.” J Obstet Gynecol Br Commons 71 (1964): 529–42.
Hibbard, B.M. “Folates and the fetus.” S Afr Med J 49.30 (1975): 1223–6.
Smithells, R.W. “The action of drugs on the embryo. Clinical aspects.” Proc R Soc Med 56 (1963): 606–8.
Smithells, R.W., Seller, M.J., Harris, R., et al. “Further experience of vitamin supplementation for prevention of neural tube defects recurrences.” Lancet 321.8832 (1983): 1027–31.
Czeizel, A.E., Dudas, I. “Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation.” New Engl J Med 327 (1992): 1832–5.
Bramswig, S., et al. “Supplementation with a multivitamin containing 800 microg of folic acid shortens the time to reach the preventive red blood cell folate concentration in healthy women.” Int J Vitam Nutr Res 79 (2009): 61–70.
Radzinskiy, V.E., Ryabinkina, T.S., Raevskaya, O.A. “Technogenic selection.” Status Praesens 5.42 (2017): 103–10.
De Batlle, J., Ferrari, P., Chajes, V., et al. “Dietary folate intake and breast cancer risk: European prospective investigation into cancer and nutrition.” J of National Cancer Institute 107.1 (2015): 367.
Metayer, C., Milne, E., Dockerty, J.D., et al. “Maternal supplementation with folic acid and other vitamins and risk of leukemia in offspring.” Epidemiology 25 (2014): 811–22.
Wang, Z.M., Zhou, B., Nie, Z.L., et al. “Folate and risk of coronary heart disease: a meta-analysis of prospective studies.” Nutr Metab Cardiovasc Dis 22.10 (2010): 890–9.
Michels, R.A., Wactavski-Wende, J., Mills, J.L., et al. “Folate, homocysteine heart defects.” Hum Reprod 32.8 (2017): 1743–50.
Micle, O., Muresan, M., Antal, L., et al. “The influence of homocysteine and oxidative stress on pregnancy outcome.” J Med Life 5.1 (2012): 68–73.
“Folates and omega-3 polyunsaturated fatty acids in obstetrics: more than prevention of neural tube defects.” Health of Ukraine. Gynecology. Obstetrics. Reproductology 1 (2018): 1–4.
Czeizel, A.E., Dudas, I., Vereczkey, A., et al. “Folate deficiency and folic acid supplementation: the prevention of neural-tube defects and congenital heart defects.” Heart Defects Nutrients 5.11 (2013): 4760–75.
Milman, N., et al. “Supplementation during pregnancy: beliefs and science.” Gynecological Endocrinology 32.7 (2016): 509–16.
Radzinskiy, V.E., et al. Pregravidary preparation: clinical protocol. Moscow. Editorial Board of Status Praesens Journal (2016): 80 p.
Pieterzik, K., Bailey, L., Shane, B. “Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics.” Clin Pharmacokinet 49.8 (2010): 535–48.
World Health Organization. Recommendations on antenatal care for a positive pregnancy. Geneva. WHO (2017). License: CC BY-NC-SA 3.0 IGO.
Ministry of Health of Ukraine. Order No. 417 dated July 16, 2011, “Organization of Outpatient Obstetric and Gynecologic Aid in Ukraine.”
Hind N. Moussa, et al. “Folic acid supplementation: what is new? Fetal, obstetric, long-term benefits and risks.” Future Sci OA 2.2 (2016): FSO116.
Kurmacheva, N.A., et al. “Pregnancy and polymorphisms of the folate cycle genes: what dose and form of folate to choose?” Doctor.ru. Gynecology. Endocrinology 14.115 (2015): 49–54.
Gromova, O.A., Torshin, I.Y., Tetruashvili, N.K., Lisitsyna, E.Y. “Systematic analysis of the relationship of vitamin deficiency and congenital malformations.” Consilium Medicum 6 (2012): 34–40.
Gosteva, E.O. Obstetric aspects of infant mortality from congenital malformations in the Perm region. Thesis abstract for PhD degree. Perm (2013): 24 p.